Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer in another Japanese molecular imaging deal

This article was originally published in Scrip

Executive Summary

Bayer Schering Pharma(BSP) has licensed exclusive global development and marketing rights to a group of cancer imaging molecules developed by the Japanese firm Hamamatsu Photonics. The radionucleotide-labelled tracers are taken up by carrier molecules highly expressed on malignant tumour cells and are used in combination with positron emission tomography (PET). The hope is that they will aid earlier and more specific identification of malignant cells, BSP said. It is the second Japanese imaging alliance in recent months for the German group. Last year, BSP acquired from Nagasaki University similar rights to molecules used in the PET imaging and diagnosis of Alzheimer's disease (Scrip Online, September 12th, 2009).

You may also be interested in...

Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise

Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent

Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts